Heron Therapeutics Company Profile (NASDAQ:HRTX)

About Heron Therapeutics

Heron Therapeutics logoHeron Therapeutics, Inc. is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company's product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology. The Company's SUSTOL (granisetron) injection, extended release is being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). HTX-019, which is an intravenous formulation of aprepitant, a neurokinin-1 (NK1) receptor antagonist, is being developed for the prevention of CINV. HTX-011, a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam, is being developed for the prevention of post-operative pain. HTX-011 is in Phase II clinical trials.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: HRTX
  • CUSIP:
Key Metrics:
  • Previous Close: $13.75
  • 50 Day Moving Average: $13.39
  • 200 Day Moving Average: $16.06
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.88
  • P/E Growth: 0.18
  • Market Cap: $N/A
  • Beta: 1.58
Profitability:
  • Return on Equity: -218.39%
  • Return on Assets: -144.10%
Debt:
  • Debt-to-Equity Ratio: 2.80%
  • Current Ratio: 3.04%
  • Quick Ratio: 2.98%
Additional Links:
Companies Related to Heron Therapeutics:

Analyst Ratings

Consensus Ratings for Heron Therapeutics (NASDAQ:HRTX) (?)
Ratings Breakdown: 9 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $37.75 (171.58% upside)

Analysts' Ratings History for Heron Therapeutics (NASDAQ:HRTX)
Show:
DateFirmActionRatingPrice TargetDetails
1/12/2017Cantor FitzgeraldSet Price TargetBuy$34.00View Rating Details
1/6/2017Cowen and CompanyReiterated RatingBuy$40.00View Rating Details
1/5/2017Jefferies Group LLCSet Price TargetBuy$40.00 -> $29.00View Rating Details
1/5/2017Leerink SwannSet Price TargetBuy$21.00View Rating Details
11/9/2016JMP SecuritiesReiterated RatingBuyView Rating Details
10/26/2016AegisInitiated CoverageBuy$41.00View Rating Details
10/4/2016Brean CapitalInitiated CoverageBuy$41.00View Rating Details
9/6/2016Lake Street CapitalReiterated RatingBuy$45.00View Rating Details
4/20/2016Noble FinancialReiterated RatingBuy$51.00View Rating Details
9/24/2015Bank of America CorpBoost Price TargetBuy$54.00View Rating Details
(Data available from 2/26/2015 forward)

Earnings

Earnings History for Heron Therapeutics (NASDAQ:HRTX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/3/2017        
2/23/2017Q4 2016($1.17)($1.22)ViewN/AView Earnings Details
11/8/2016Q3 2016($1.17)($1.24)ViewN/AView Earnings Details
5/5/2016Q1($0.92)($0.92)ViewN/AView Earnings Details
2/19/2016Q4($0.64)($0.87)ViewN/AView Earnings Details
11/6/2015Q3($0.67)($0.63)ViewN/AView Earnings Details
8/7/2015($0.65)($0.74)ViewN/AView Earnings Details
5/8/2015Q115($0.68)($0.70)ViewN/AView Earnings Details
3/13/2015($0.79)($0.71)ViewN/AView Earnings Details
11/6/2014($0.69)($0.66)ViewN/AView Earnings Details
8/4/2014($0.62)($0.78)ViewN/AView Earnings Details
5/8/2014($0.67)($0.74)ViewN/AView Earnings Details
3/5/2014($0.53)($0.75)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Heron Therapeutics (NASDAQ:HRTX)
Current Year EPS Consensus Estimate: $-3.98 EPS
Next Year EPS Consensus Estimate: $-2.02 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($1.21)($0.90)($1.06)
Q2 20163($0.98)($0.92)($0.95)
Q3 20163($1.19)($1.01)($1.09)
Q4 20163($1.18)($0.82)($1.00)
Q1 20171($0.86)($0.86)($0.86)
Q2 20171($1.04)($1.04)($1.04)
Q3 20171($0.80)($0.80)($0.80)
Q4 20171($0.72)($0.72)($0.72)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Heron Therapeutics (NASDAQ:HRTX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Heron Therapeutics (NASDAQ:HRTX)
Insider Ownership Percentage: 20.31%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/19/2017Kevin C TangDirectorBuy2,459,016$12.20$29,999,995.20View SEC Filing  
8/10/2016Robert RosenInsiderSell100,000$23.30$2,330,000.00View SEC Filing  
4/21/2016Robert RosenPresidentSell200,000$23.23$4,646,000.00View SEC Filing  
6/10/2015Kevin C TangDirectorBuy121,212$24.75$2,999,997.00View SEC Filing  
6/2/2015Kevin C TangDirectorBuy150,000$20.62$3,093,000.00View SEC Filing  
6/1/2015Kimberly ManhardDirectorSell2,708$21.17$57,328.36View SEC Filing  
6/25/2014Barry D QuartCEOBuy10,000$11.75$117,500.00View SEC Filing  
6/25/2014Kevin C TangDirectorBuy510,638$11.75$5,999,996.50View SEC Filing  
11/20/2013Barry D QuartCEOBuy1,000,000$0.40$400,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Heron Therapeutics (NASDAQ:HRTX)
DateHeadline
News IconWilliams %R Check on Shares of Heron Therapeutics Inc (HRTX) - Piedmont Register (NASDAQ:HRTX)
piedmontregister.com - February 25 at 12:05 AM
businesswire.com logoHeron Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results and Recent Corporate Progress - Business Wire (press release) (NASDAQ:HRTX)
www.businesswire.com - February 25 at 12:05 AM
streetinsider.com logoHeron Therapeutics (HRTX) Announces Inclusion of SUSTOL ER Injection in NCCN Antiemesis Guidelines (NASDAQ:HRTX)
www.streetinsider.com - February 24 at 10:32 AM
us.rd.yahoo.com logoHeron Therapeutics Announces Inclusion of SUSTOL® (Granisetron) Extended-Release Injection in NCCN® Antiemesis Guidelines (NASDAQ:HRTX)
us.rd.yahoo.com - February 24 at 10:32 AM
us.rd.yahoo.com logo8:02 am Heron Therapeutics announces the inclusion of Sustol extended-release injection as part of the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for Antiemesis Version 1.2017 (NASDAQ:HRTX)
us.rd.yahoo.com - February 24 at 10:32 AM
sg.finance.yahoo.com logoHeron Therapeutics reports 4Q loss (NASDAQ:HRTX)
sg.finance.yahoo.com - February 23 at 10:47 PM
finance.yahoo.com logoHeron Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results and Recent Corporate Progress (NASDAQ:HRTX)
finance.yahoo.com - February 23 at 5:46 PM
biz.yahoo.com logoHERON THERAPEUTICS, INC. /DE/ Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements (NASDAQ:HRTX)
biz.yahoo.com - February 23 at 5:46 PM
News IconAre Analysts Optimistic About Where Heron Therapeutics, Inc. (NASDAQ:HRTX) is Heading? - Winfield Review (NASDAQ:HRTX)
winfieldreview.com - February 18 at 7:07 AM
News IconHeron Therapeutics, Inc. (NASDAQ:HRTX) Quarterly EPS Projection At $-1.13 - Stock Observer (NASDAQ:HRTX)
www.thestockobserver.com - February 13 at 11:27 AM
News IconNews Impact Score Of Heron Therapeutics, Inc. (NASDAQ:HRTX) At 37 - Stock Observer (NASDAQ:HRTX)
www.thestockobserver.com - February 10 at 4:39 AM
us.rd.yahoo.com logoHeron Therapeutics to Present at the Leerink Partners 6th Annual Global Healthcare Conference (NASDAQ:HRTX)
us.rd.yahoo.com - February 8 at 6:22 PM
finance.yahoo.com logoLifeSci Capital Initiates Coverage of Heron Therapeutics (NASDAQ:HRTX)
finance.yahoo.com - February 7 at 7:02 PM
investornewswire.com logoSentiments And Ratings Alert: Heron Therapeutics, Inc. (NASDAQ:HRTX) - Investor Newswire (NASDAQ:HRTX)
www.investornewswire.com - February 5 at 5:29 PM
4-traders.com logoHeron Therapeutics : Announces Underwriters’ Exercise in Full of Option to Purchase Additional Shares (NASDAQ:HRTX)
www.4-traders.com - January 31 at 11:29 PM
businesswire.com logoHeron Therapeutics Announces Underwriters' Exercise in Full of Option to Purchase Additional Shares - Business Wire (press release) (NASDAQ:HRTX)
www.businesswire.com - January 31 at 6:28 PM
finance.yahoo.com logoHeron Therapeutics Announces Underwriters’ Exercise in Full of Option to Purchase Additional Shares (NASDAQ:HRTX)
finance.yahoo.com - January 31 at 6:28 PM
News IconHeron Therapeutics Inc HRTX Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:HRTX)
www.bioportfolio.com - January 29 at 4:10 AM
News IconShares in Focus: Heron Therapeutics Inc. (HRTX) - Sherwood Daily (NASDAQ:HRTX)
sherwooddaily.com - January 28 at 5:55 PM
News IconTechnical Updates on Shares of Heron Therapeutics Inc. (HRTX) - Market Point (NASDAQ:HRTX)
mtptnews.com - January 26 at 7:20 PM
News IconNews Impact Score Of Heron Therapeutics, Inc. (NASDAQ:HRTX) At 0 - Stock Observer (NASDAQ:HRTX)
www.thestockobserver.com - January 26 at 7:20 PM
News IconEarnings in Full Force, Analysts Take Aim at Heron Therapeutics, Inc. (NASDAQ:HRTX) - Wall Street Beacon (NASDAQ:HRTX)
wsbeacon.com - January 26 at 7:20 PM
News IconShares in Focus: Heron Therapeutics, Inc. (NASDAQ:HRTX) - The Tribune (NASDAQ:HRTX)
lakecitytribune.com - January 25 at 8:17 PM
thestreet.com logoFirst Week Of HRTX September 15th Options Trading (NASDAQ:HRTX)
www.thestreet.com - January 25 at 3:15 PM
biz.yahoo.com logoHERON THERAPEUTICS, INC. /DE/ Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Fi (NASDAQ:HRTX)
biz.yahoo.com - January 24 at 6:31 PM
News IconSell-side is Weighing in on Heron Therapeutics, Inc. (NASDAQ:HRTX) Earnings - Aiken Advocate (NASDAQ:HRTX)
aikenadvocate.com - January 22 at 5:39 PM
News IconShares in Focus: Heron Therapeutics Inc. (HRTX) - Springdale Times (NASDAQ:HRTX)
springdaletimes.com - January 22 at 5:39 PM
investopedia.com logoHeron Declares $150 Million Public Offering (HRTX) (NASDAQ:HRTX)
www.investopedia.com - January 21 at 2:00 AM
News IconHeron Therapeutics Inc. (HRTX) Given Consensus Recommendation of "Buy" by Analysts (NASDAQ:HRTX)
larampadinapoli.com - January 21 at 2:00 AM
investopedia.com logoHeron Therapeutics Launches $150M Public Offering (NASDAQ:HRTX)
www.investopedia.com - January 20 at 3:57 PM
4-traders.com logoHeron Therapeutics : Announces Proposed Public Offering of Common Stock (NASDAQ:HRTX)
www.4-traders.com - January 20 at 12:30 AM
News IconAmplified Volatility Spotted in Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) - Wall Street Beacon (NASDAQ:HRTX)
wsbeacon.com - January 19 at 7:29 PM
streetinsider.com logoHeron Therapeutics (HRTX) Prices Offering at $12.20/Share - StreetInsider.com (NASDAQ:HRTX)
www.streetinsider.com - January 19 at 7:29 PM
finance.yahoo.com logoHeron Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock (NASDAQ:HRTX)
finance.yahoo.com - January 19 at 7:29 PM
streetinsider.com logoHeron Therapeutics (HRTX) to Offer $150M in Common Stock - StreetInsider.com (NASDAQ:HRTX)
www.streetinsider.com - January 18 at 6:13 PM
finance.yahoo.com logoHeron Therapeutics Announces Proposed Public Offering of Common Stock (NASDAQ:HRTX)
finance.yahoo.com - January 18 at 6:13 PM
News IconHeron Announces Submission of Cinvanti NDA for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) (NASDAQ:HRTX)
www.drugs.com - January 17 at 11:18 AM
News IconEPS Of Heron Therapeutics, Inc. (NASDAQ:HRTX) At $-1.13 - Stock Observer (NASDAQ:HRTX)
www.thestockobserver.com - January 15 at 5:26 PM
streetinsider.com logoHeron Therapeutics (HRTX) Submits NDA for CINVANTI to Prevent CINV (NASDAQ:HRTX)
www.streetinsider.com - January 12 at 11:16 PM
News IconWill The Needle Move For Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:HRTX)
wsbeacon.com - January 12 at 6:14 PM
streetinsider.com logoHeron Therapeutics (HRTX) Submits NDA for CINVANTI to Prevent CINV - StreetInsider.com (NASDAQ:HRTX)
www.streetinsider.com - January 12 at 6:14 PM
finance.yahoo.com logoHeron Announces Submission of CINVANTI™ NDA for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) (NASDAQ:HRTX)
finance.yahoo.com - January 12 at 6:14 PM
finance.yahoo.com logo8:33 am Heron Therapeutics announced submission of the NDA for CINVANTI (HTX-019) to the FDA (NASDAQ:HRTX)
finance.yahoo.com - January 12 at 6:14 PM
News IconHeron Therapeutics Inc (NASDAQ:HRTX) Heffx Technical Analysis - Live Trading News (NASDAQ:HRTX)
www.livetradingnews.com - January 9 at 6:26 PM
istreetwire.com logoStocks Alert: Plains All American Pipeline, L.P. (PAA), Heron Therapeutics, Inc. (HRTX), Stryker Corporation (SYK) - iStreetWire (NASDAQ:HRTX)
istreetwire.com - January 9 at 6:26 PM
marketexclusive.com logoAnalyst Activity – Cowen and Company Reiterates Buy on Heron Therapeutics (NASDAQ:HRTX) (NASDAQ:HRTX)
marketexclusive.com - January 7 at 7:36 PM
marketexclusive.com logoAnalyst Activity – Cantor Fitzgerald Reiterates Overweight on Heron Therapeutics (NASDAQ:HRTX) (NASDAQ:HRTX)
marketexclusive.com - January 7 at 3:54 AM
smarteranalyst.com logoStock Update (NASDAQ:HRTX): Heron Therapeutics Inc. Announces Positive Topline Results From Phase 2 Clinical ... - Smarter Analyst (NASDAQ:HRTX)
www.smarteranalyst.com - January 6 at 4:51 AM
News IconHeron Therapeutics Inc (NASDAQ:HRTX) Bearish Long Term Projection - Live Trading News (NASDAQ:HRTX)
www.livetradingnews.com - January 6 at 4:51 AM
streetinsider.com logoHeron Therapeutics (HRTX) HTX-011 Demonstrated Statistically Significance in Phase 2 Trial - StreetInsider.com (NASDAQ:HRTX)
www.streetinsider.com - January 6 at 4:51 AM

Social

What is Heron Therapeutics' stock symbol?

Heron Therapeutics trades on the NASDAQ under the ticker symbol "HRTX."

Where is Heron Therapeutics' stock going? Where will Heron Therapeutics' stock price be in 2017?

9 equities research analysts have issued 12 month target prices for Heron Therapeutics' stock. Their predictions range from $21.00 to $51.00. On average, they expect Heron Therapeutics' stock price to reach $37.75 in the next twelve months.

When will Heron Therapeutics announce their earnings?

Heron Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, May, 3rd 2017.

What are analysts saying about Heron Therapeutics stock?

Here are some recent quotes from research analysts about Heron Therapeutics stock:

  • According to Zacks Investment Research, "Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA. " (1/10/2017)

  • Cowen and Company analysts commented, "Yesterday Heron released positive Ph 2 abdominoplasty data for HTX-011." (1/6/2017)

Who owns Heron Therapeutics stock?

Heron Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Franklin Resources Inc. (0.00%), FMR LLC (0.00%), Janus Capital Management LLC (0.00%), Broadfin Capital LLC (0.00%), Highland Capital Management LP (0.00%) and State Street Corp (0.00%). Company insiders that own Heron Therapeutics stock include Kevin C Tang, Kimberly Manhard and Robert Rosen.

Who sold Heron Therapeutics stock? Who is selling Heron Therapeutics stock?

Heron Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Allianz Asset Management AG and Franklin Resources Inc..

Who bought Heron Therapeutics stock? Who is buying Heron Therapeutics stock?

Heron Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Highland Capital Management LP, Broadfin Capital LLC, Rubric Capital Management LP, Janus Capital Management LLC, Alyeska Investment Group L.P., State Street Corp, Eventide Asset Management LLC and Alden Global Capital LLC.

How do I buy Heron Therapeutics stock?

Shares of Heron Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Heron Therapeutics stock cost?

One share of Heron Therapeutics stock can currently be purchased for approximately $13.90.

Heron Therapeutics (NASDAQ:HRTX) Chart for Sunday, February, 26, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Heron Therapeutics (NASDAQ:HRTX)

Earnings History Chart

Earnings by Quarter for Heron Therapeutics (NASDAQ:HRTX)

Dividend History Chart

Dividend Payments by Quarter for Heron Therapeutics (NASDAQ:HRTX)

Last Updated on 2/26/2017 by MarketBeat.com Staff